Fidelity Investments
KLRS

Fidelity Investments’s Kalaris Therapeutics KLRS Stock Holding History

Fidelity Investments’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45K Hold
7,806
– – ﹤0.01% 4174
2025
Q4 		$65.9K Hold
7,806
– – ﹤0.01% 3968
2025
Q3 		$45.1K Hold
7,806
– – ﹤0.01% 4020
2025
Q2 		$20.8K Hold
7,806
– – ﹤0.01% 4265
2025
Q1 		$62.7K Sell
7,806
-6,034
-44% -$59.1K ﹤0.01% 3758
2024
Q4 		$134K Buy
13,840
+335
+2% +$5.07K ﹤0.01% 3421
2024
Q3 		$251K Buy
13,505
+76
+0.6% +$1.33K ﹤0.01% 3121
2024
Q2 		$223K Buy
13,429
+1,610
+14% +$28.4K ﹤0.01% 2990
2024
Q1 		$205K Sell
11,819
-235,693
-95% -$3.85M ﹤0.01% 3022
2023
Q4 		$3.87M Sell
247,512
-173,465
-41% -$6.84M ﹤0.01% 2130
2023
Q3 		$20.8M Buy
420,977
+6,997
+2% +$477K ﹤0.01% 1573
2023
Q2 		$32.4M Buy
413,980
+93,561
+29% +$8.89M ﹤0.01% 1435
2023
Q1 		$29M Buy
320,419
+14,055
+5% +$1.79M ﹤0.01% 1461
2022
Q4 		$36.1M Sell
306,364
-10,411
-3% -$1.77M ﹤0.01% 1387
2022
Q3 		$57.5M Buy
316,775
+4,258
+1% +$664K 0.01% 1194
2022
Q2 		$28M Sell
312,517
-32,550
-9% -$3.41M ﹤0.01% 1516
2022
Q1 		$53.6M Buy
345,067
+24,151
+8% +$4.82M ﹤0.01% 1362
2021
Q4 		$95.5M Buy
320,916
+2,230
+0.7% +$1.03M 0.01% 1117
2021
Q3 		$184M Buy
318,686
+38,392
+14% +$17.8M 0.01% 843
2021
Q2 		$127M Sell
280,294
-22,265
-7% -$11.5M 0.01% 1017
2021
Q1 		$163M Sell
302,559
-9,508
-3% -$7.99M 0.01% 879
2020
Q4 		$270M Buy
312,067
+23,961
+8% +$18.4M 0.02% 627
2020
Q3 		$173M Buy
+288,106
New +$197M 0.02% 688

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Fidelity Investments's KLRS Position: Q1 2026 in Review

Fidelity Investments held its Kalaris Therapeutics (KLRS) position steady in Q1 2026 at 7,806 shares worth $45K. The position accounts for ﹤0.01% of the portfolio, ranked #4174.

Fidelity Investments first reported a position in KLRS in Q3 2020 and has held it in 23 quarters since. The position peaked at $270M in Q4 2020. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Fidelity Investments held 7,806 shares of Kalaris Therapeutics worth $45K as of Q1 2026.
  • Fidelity Investments left its Kalaris Therapeutics share count unchanged in Q1 2026.
  • Kalaris Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4174 holding.
  • Fidelity Investments first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Fidelity Investments's Kalaris Therapeutics position peaked at $270M in Q4 2020.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.